Frontage Laboratories Executive and Leadership Team

Zhongping Lin, the Co-Chief Executive Officer at Frontage Laboratories, directs the overarching corporate strategy and long-term vision for the organization. By aligning internal research capabilities with the evolving needs of the global biotechnology sector, Lin ensures the company maintains a competitive edge in drug metabolism and pharmacokinetics. This leadership role involves constant collaboration with the Board to secure sustainable growth and market expansion across North America and Asia. Zhongping Lin monitors the integration of analytical testing and formulation development services to guarantee high-quality outcomes for pharmaceutical clients. Through the optimization of preclinical and clinical trial material manufacturing processes, the Co-Chief Executive Officer drives operational excellence. By fostering a culture of scientific rigor, Lin enables the firm to support complex molecule development cycles effectively. Ultimately, the Co-Chief Executive Officer secures the company's position as a premier partner for drug discovery and regulatory submission success.

Huan Wang, the Interim Chief Financial Officer at Frontage Laboratories, directs the financial planning, reporting, and capital allocation strategies for the organization. Overseeing the fiscal health of the company, the Interim Chief Financial Officer ensures that investments in laboratory technology and scientific talent align with long-term growth objectives. This role involves managing complex financial structures to support the expansion of clinical trial material manufacturing and bioanalysis services. Huan Wang monitors budgetary performance across all business units to maintain profitability while funding critical research initiatives. By providing data-driven insights to the executive team, the Interim Chief Financial Officer facilitates informed decision-making regarding market entry and service diversification. This leadership position requires rigorous oversight of financial compliance and risk management protocols. Through the optimization of capital resources, Wang secures the financial stability necessary for the firm to continue providing high-value, science-driven solutions to biotechnology and pharmaceutical partners worldwide.

Min Wang, the Chief Operating Officer at Frontage Laboratories, manages the daily execution of integrated service delivery across all laboratory facilities. Overseeing the infrastructure for bioanalysis and preclinical safety assessment, the Chief Operating Officer ensures that every project meets stringent quality standards and client timelines. This role requires constant coordination with department heads to streamline workflows and maximize resource allocation during the drug development process. Min Wang implements advanced operational protocols to enhance efficiency in toxicology assessments and early phase clinical studies. By refining internal systems, the Chief Operating Officer supports the company's mission to advance molecules through development stages with precision. This leadership position involves managing cross-functional teams to maintain high throughput in analytical testing. Through the continuous improvement of operational frameworks, Wang directly impacts the firm's ability to handle diverse client portfolios, ensuring that all laboratory operations remain scalable and responsive to international regulatory requirements.

Abdul Mutlib, the Scientific Strategy Chief & Officer & President, Canada at Frontage Laboratories, architects the technical roadmap and scientific innovation agenda for the entire organization. Overseeing the expansion of research capabilities in the Canadian market, the Scientific Strategy Chief & Officer & President, Canada ensures that all preclinical and clinical services remain at the forefront of industry standards. This role involves guiding the development of novel methodologies for drug metabolism and pharmacokinetics to address the unique challenges of modern drug discovery. Abdul Mutlib collaborates with global scientific teams to integrate advanced analytical testing into the broader service portfolio. By driving scientific excellence, the Scientific Strategy Chief & Officer & President, Canada enables the firm to support complex regulatory submissions across multiple international jurisdictions. This leadership position requires constant evaluation of emerging technologies to maintain the company's reputation for scientific integrity. Through strategic oversight, Mutlib ensures that all research initiatives directly contribute to the successful advancement of client molecules.